Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients
| Autor: | Anne Räisänen-Sokolowski, Akseli Hemminki, Vincenzo Cerullo, Laura Ahtiainen, Iulia Diaconu, Lotta Kangasniemi, Eerika Karli, Kilian Guse, Ari Ristimäki, Matteo Ugolini, Sari Pesonen, Elina Haavisto, Sirkka-Liisa Holm, Andreas Helminen, Merja Särkioja, Mauri Kouri, Sophie Escutenaire, Timo Joensuu, Maria Rajecki, Petri Nokisalmi, Minna Oksanen, Anna Kanerva, Leena Laasonen, Aila Karioja-Kallio, Petteri Arstila, Mari Raki |
|---|---|
| Přispěvatelé: | Cerullo, Vincenzo, Pesonen, Sari, Diaconu, Iulia, Escutenaire, Sophie, Arstila, Petteri T., Ugolini, Matteo, Nokisalmi, Petri, Raki, Mari, Laasonen, Leena, Särkioja, Merja, Rajecki, Maria, Kangasniemi, Lotta, Guse, Kilian, Helminen, Andrea, Ahtiainen, Laura, Ristimäki, Ari, Räisänen-Sokolowski, Anne, Haavisto, Elina, Oksanen, Minna, Karli, Eerika, Karioja-Kallio, Aila, Holm, Sirkka-Liisa, Kouri, Mauri, Joensuu, Timo, Kanerva, Anna, Hemminki, Akseli |
| Rok vydání: | 2010 |
| Předmět: |
Oncolytic adenovirus
Cancer Research Survivin T-Lymphocytes Epitopes T-Lymphocyte Biology Transfection Adenoviridae Inhibitor of Apoptosis Proteins 03 medical and health sciences 0302 clinical medicine Immunity Cricetinae Neoplasms Inhibitor of Apoptosis Protein Granulocyte Colony-Stimulating Factor medicine Macrophage Cytotoxic T cell Animals Humans 030304 developmental biology Oncolytic Virotherapy 0303 health sciences Animal ELISPOT Microtubule-Associated Protein Cancer medicine.disease 3. Good health Oncolytic virus Granulocyte macrophage colony-stimulating factor T-Lymphocyte Oncology 030220 oncology & carcinogenesis Immunology Neoplasm Immunotherapy Microtubule-Associated Proteins medicine.drug Human |
| Zdroj: | Cancer research. 70(11) |
| ISSN: | 1538-7445 |
| Popis: | Granulocyte macrophage colony-stimulating factor (GMCSF) can mediate antitumor effects by recruiting natural killer cells and by induction of tumor-specific cytotoxic T-cells through antigen-presenting cells. Oncolytic tumor cell–killing can produce a potent costimulatory danger signal and release of tumor epitopes for antigen-presenting cell sampling. Therefore, an oncolytic adenovirus coding for GMCSF was engineered and shown to induce tumor-specific immunity in an immunocompetent syngeneic hamster model. Subsequently, 20 patients with advanced solid tumors refractory to standard therapies were treated with Ad5-D24-GMCSF. Of the 16 radiologically evaluable patients, 2 had complete responses, 1 had a minor response, and 5 had disease stabilization. Responses were frequently seen in injected and noninjected tumors. Treatment was well tolerated and resulted in the induction of both tumor-specific and virus-specific immunity as measured by ELISPOT and pentamer analysis. This is the first time that oncolytic virus–mediated antitumor immunity has been shown in humans. Ad5-D24-GMCSF is promising for further clinical testing. Cancer Res; 70(11); 4297–309. ©2010 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|